Aaron M Carlson1, Irene C Huffnagel2, Aad Verrips3, Marjo S van der Knaap2, Marc Engelen2, Keith Van Haren4. 1. Department of Neurology, University of Colorado, Denver, CO, USA. 2. Department of Pediatric Neurology, Emma Children's Hospital, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands. 3. Department of Neurology, Canisius-Wilhelmina Hospital, Nijmegen, The Netherlands. 4. Department of Pediatric Neurology, Lucille-Packard Children's Hospital, Stanford University School of Medicine, Stanford, CA, USA. kpv@stanford.edu.
Abstract
BACKGROUND: X-linked adrenoleukodystrophy (ALD) is the most common genetic peroxisomal disorder with an estimated prevalence of 1:15,000. Approximately two-thirds of males with ALD manifest the inflammatory demyelinating cerebral phenotype (cALD) at some disease stage, in which focal, inflammatory lesions progress over months to years. Hematopoietic stem-cell transplantation can permanently halt cALD progression, but it is only effective if initiated early. Although most cALD lesions progress relentlessly, a subset may spontaneously arrest; subsequent reactivation of these arrested lesions has not been previously detailed. OBJECTIVE: We describe a novel arresting-relapsing variant of cALD. METHODS: Salient clinical and radiographic studies were reviewed and summarized for cALD patients with episodic deteriorations. RESULTS: We report a series of five unrelated men with spontaneously arrested cALD lesions that subsequently manifested signs of clinical and radiologic lesion progression during longitudinal follow-up. In three of five patients, functional status was too poor to attempt transplant by the time the recurrence was identified. One patient experienced reactivation followed by another period of spontaneous arrest. CONCLUSIONS: These cases emphasize the need for continued clinical and radiologic vigilance for adult men with ALD to screen for evidence of new or reactivated cALD lesions to facilitate prompt treatment evaluation.
BACKGROUND: X-linked adrenoleukodystrophy (ALD) is the most common genetic peroxisomal disorder with an estimated prevalence of 1:15,000. Approximately two-thirds of males with ALD manifest the inflammatory demyelinating cerebral phenotype (cALD) at some disease stage, in which focal, inflammatory lesions progress over months to years. Hematopoietic stem-cell transplantation can permanently halt cALD progression, but it is only effective if initiated early. Although most cALD lesions progress relentlessly, a subset may spontaneously arrest; subsequent reactivation of these arrested lesions has not been previously detailed. OBJECTIVE: We describe a novel arresting-relapsing variant of cALD. METHODS: Salient clinical and radiographic studies were reviewed and summarized for cALD patients with episodic deteriorations. RESULTS: We report a series of five unrelated men with spontaneously arrested cALD lesions that subsequently manifested signs of clinical and radiologic lesion progression during longitudinal follow-up. In three of five patients, functional status was too poor to attempt transplant by the time the recurrence was identified. One patient experienced reactivation followed by another period of spontaneous arrest. CONCLUSIONS: These cases emphasize the need for continued clinical and radiologic vigilance for adult men with ALD to screen for evidence of new or reactivated cALD lesions to facilitate prompt treatment evaluation.
Authors: Weston P Miller; Steven M Rothman; David Nascene; Teresa Kivisto; Todd E DeFor; Richard S Ziegler; Julie Eisengart; Kara Leiser; Gerald Raymond; Troy C Lund; Jakub Tolar; Paul J Orchard Journal: Blood Date: 2011-05-17 Impact factor: 22.113
Authors: Marc Engelen; Stephan Kemp; Marianne de Visser; Björn M van Geel; Ronald J A Wanders; Patrick Aubourg; Bwee Tien Poll-The Journal: Orphanet J Rare Dis Date: 2012-08-13 Impact factor: 4.123
Authors: Afonso P Liberato; Eric J Mallack; Razina Aziz-Bose; Doug Hayden; Arne Lauer; Paul A Caruso; Patricia L Musolino; Florian S Eichler Journal: Neurology Date: 2019-03-22 Impact factor: 11.800
Authors: Eric James Mallack; Keith P Van Haren; Anna Torrey; Stephanie van de Stadt; Marc Engelen; Gerald V Raymond; Ali Fatemi; Florian S Eichler Journal: Neurology Date: 2022-05-24 Impact factor: 11.800